CANbridge In The Book “Inside the Orphan Drug Revolution

A widely recognized leader in the rare disease field, Jim Geraghty, has published his new book “Inside the Orphan Drug Revolution”, an epic reading on his personal recount how the orphan drug industry developed over the past forty years as an entrepreneur, a leader, an insider and important contributor.
Forty years ago, a revolution started that transformed the prospects of patients with rare diseases. This book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen, and it tells deeply personal stories of patients and parents willing to risk new, untried therapies. CANbridge is honored to be part of this revolution and has been mentioned as the “Genzyme of China” in this book.
In this book, Jim once again highlighted CANbridge’s vision to bring proven orphan drugs to China and to develop new ones there to bring to the U.S. and other markets. He also laid out how CANbridge develop in the past years to address the growing, yet unaddressed orphan drugs market in China. For more details about the revolution of the orphan drugs industry, please go to "Inside the Orphan Drug Revolution".



About Jim Geraghty

A widely recognized leader in the rare disease field, Jim Geraghty has been a director or chair of seven NASDAQ-listed biotech companies. He's worked on orphan drugs for more than 40 years―as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. A former trustee of Harvard Medical School's renowned Joslin Diabetes Center, he's spoken before both houses of Congress, at the World Economic Forum, and at many other high-profile conferences. A Georgetown graduate with a masters in psychology from Penn and a law degree from Yale, he is a citizen of three countries and lives in Boston.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School, the University of Washington School of Medicine, Scriptr Global and LogicBio.
For more on CANbridge Pharmaceuticals Inc., please go to:

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.



U.S. Investor Relations:

Chris Brinzey

ICR Westwicke

China Investor Relations

CANbridge Pharmaceuticals Inc.


Deanne Eagle

Planet Communications